Anthem Blue Cross Blue Shield Joins List of 60 Commercial Plans Covering Avedro’s FDA-Approved Corneal Cross-Linking Procedure

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc., a leading commercial-stage ophthalmic medical technology company and a global leader in corneal remodeling, today announced that Anthem, the largest member of the Blue Cross Blue Shield Association, has issued a positive coverage policy for Avedro’s FDA-approved corneal cross-linking procedure bringing the total number of commercial plans covering the Photrexa® drug formulations and the KXL® System to 60. The addition of the nation’s second largest

Full Story →